Your thoughts on... the economy

Article

This month's topic: professional expenditure

Key Points

Here at Ophthalmology Times Europe, we were interested to see how you think the seemingly ever-worsening economic climate would impact on professional expenditure this year, and we were surprised by the results of our enquiries.

In answer to the question "How do you think your professional expenditure will change in 2009 compared with 2008?",1 only 32% of survey respondents answered that they were planning to reduce their expenditure (to varying degrees) this year. The most common single response was "I plan to spend about the same" (29%), and the remaining 39% are in fact planning to increase professional expenditure this year to varying degrees.

The polarity of the responses to the question "How much do you plan to spend on new products and equipment this year?"3 was striking. In contrast to earlier results, this survey revealed that ophthalmologists in fact intend to spend either very little or very large sums in 2009: a large proportion of respondents (33%) are expecting to spend over €500,000 on new products and equipment, although slightly more (38%) intend to spend no more than €50,000.

Overall, however, despite the relative caution in terms of money spent on acquiring new products and equipment, it seems that the European ophthalmology market is starting 2009 from a healthy position.

-----------------

1. OTE online survey; http://www.oteurope.com/, December 2008.

2. OTE online survey; http://www.oteurope.com/, November 2008.

3. OTE online survey; http://www.oteurope.com/, January 2009. Results correct at the time of going to press.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.